Objective To investigate the current situation of clinical studies on puerarin for angina pectoris and assess whether it is adequate to provide evidence for clinical practiice.
Methods We collected all the published clinical studies on puerarin for angina pectoris from 1966 to October 2003, and assessed all the included reports according to international clinical epidemiological standard.
Results 106 RCTs, 8 non-randomized controlled studies and 24 case series were included and analyzed. 126 studies reported diagnosis criteria, 10 desccribed inclusion criteria; 3 studies were quasi-random, 1 double blind, 4 single blind; no study reported follow-up; 117 studies reported adverse effects.
Conclusions Currently the quality of studies on puerarin for angina pectoris is not good enough to provide reliable evidence for clinical practice.
Citation：
LONG Bo,CHEN Yucheng,CHEN Huaisheng,ZENG Zhi. Ouality Assessment of Clinical Studies on Puerarin for Angina Pectoris. Chinese Journal of Evidence-Based Medicine, 2004, 04(5): 333-336. doi:
Copy
Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved
| 1. |
［1］Beller. George A. Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2001 ;103(20) :2 428-2 435.
|
| 2. |
［2］Wang L, Zhai AP, Chai XS. The Vitro Action of Purarin On Cats Vascular Smooth Muscle[J]. Acta Pharmacologica Sinica,1994;15(2) :180 -182.
|
| 3. |
［3］Zhou JH, Zhou H, Liu XR. Effet of Purarin Injection on Blood Fat and Hemotheology[J]. J Med Thero ＆ Prac, 2000;13(1) :40.
|
| 4. |
［4］Clarke M, Oxman AD, editors. Cochrane Reviever’ s handbook 4.1 [ M/CD ] [ Update 2000 ]. In Review Manager (RevMan) [ Computer program], Version4.1. Oxford, England: The Cochrane Collaboration, 2000.
|
| 5. |
［5］Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, McQuary HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ] ? Controlled Clin Trials, 1996 ; 17(1): 1-12.
|
| 6. |
［6］Liu M, Zhang SH. New Knowledge: Intention-to-Treat Analysis in Clinical Trail[J]. BMJ Chinese Edition, 2001;4(4) :223 -224.
|
| 7. |
刘鸣,张世洪.新知识:临床试验中的意向处理分析[J].英国医学杂志中文版,2001;4(4):223～224.
|
- 1. ［1］Beller. George A. Coronary Heart Disease in the First 30 Years of the 21st Century: Challenges and Opportunities: The 33rd Annual James B. Herrick Lecture of the Council on Clinical Cardiology of the American Heart Association[J]. Circulation,2001 ;103(20) :2 428-2 435.
- 2. ［2］Wang L, Zhai AP, Chai XS. The Vitro Action of Purarin On Cats Vascular Smooth Muscle[J]. Acta Pharmacologica Sinica,1994;15(2) :180 -182.
- 3. ［3］Zhou JH, Zhou H, Liu XR. Effet of Purarin Injection on Blood Fat and Hemotheology[J]. J Med Thero ＆ Prac, 2000;13(1) :40.
- 4. ［4］Clarke M, Oxman AD, editors. Cochrane Reviever’ s handbook 4.1 [ M/CD ] [ Update 2000 ]. In Review Manager (RevMan) [ Computer program], Version4.1. Oxford, England: The Cochrane Collaboration, 2000.
- 5. ［5］Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ,Gavaghan DJ, McQuary HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary [ J ] ? Controlled Clin Trials, 1996 ; 17(1): 1-12.
- 6. ［6］Liu M, Zhang SH. New Knowledge: Intention-to-Treat Analysis in Clinical Trail[J]. BMJ Chinese Edition, 2001;4(4) :223 -224.
- 7. 刘鸣,张世洪.新知识:临床试验中的意向处理分析[J].英国医学杂志中文版,2001;4(4):223～224.
